Trials / Completed
CompletedNCT02392507
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Necitumumab | Administered IV |
| DRUG | Nab-Paclitaxel | Administered IV |
| DRUG | Carboplatin | Administered IV |
Timeline
- Start date
- 2015-10-12
- Primary completion
- 2018-01-29
- Completion
- 2019-11-06
- First posted
- 2015-03-19
- Last updated
- 2020-11-19
- Results posted
- 2019-02-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02392507. Inclusion in this directory is not an endorsement.